Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

The Lupus Research Institute (LRI) today announced the first $1 million research grants given to lupus investigators by a private research organization. The LRI Distinguished Innovator Initiative was ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

the maker of Froot Loops and Apple Jacks, announced nearly a decade ago that it would remove artificial colors and ingredients from its products by 2018. Get any of our free email newsletters ...

Systemic lupus is the most common form of lupus—it’s what most people mean when they refer to “lupus.” Systemic lupus can be mild or severe. Cutaneous lupus erythematosus This form of lupus is limited ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

known as lupus nephritis (LN). Credit: SciePro via Shutterstock. Clinical stage biopharma company Kezar Life Sciences is discontinuing its LN clinical programme following the death of four patients.

After hours: October 21 at 5:05 PM EDT Loading Chart for LOOP ...

What kind of doctor treats lupus? It's a common question for those who may have or have been diagnosed with systemic lupus erythematosus (SLE) or another form of lupus. Since most people with lupus ...

CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor ...